Philippines Drug Market More Than Doubles In 10 Years
This article was originally published in PharmAsia News
The Philippines' pharmaceuticals market probably has more than doubled in the past 10 years, from one worth about $976 million in 1999 to about $2.1 billion today. One of the reasons is the country remains one of the world's largest per capita buyers of medicines, equaling half of its health spending. Fewer than one-third of sales in the Philippines are generated by local drug makers, leading to drug prices two to 30 times higher for branded drugs than in surrounding Asian countries or in Canada. Generics account for 4 percent of total sales. (Click here for more
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.